Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics for fibrotic diseases, solid tumors and muscular dystrophies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Pliant’s clinical programs and corporate strategy evolve over time.
In its recent press releases, Pliant has highlighted several key themes. The company has reported interim and ongoing data from a Phase 1, open-label, dose-escalation trial of PLN-101095, an oral dual-selective inhibitor of integrins αvβ8 and αvβ1, in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors. These updates describe antitumor activity, including partial and complete responses in certain dose cohorts when PLN-101095 is combined with pembrolizumab, as well as safety and pharmacokinetic observations.
Pliant’s news flow has also covered developments in its bexotegrast (PLN-74809) program in idiopathic pulmonary fibrosis, including the termination and close-out of the BEACON-IPF Phase 2b/3 trial and the company’s decision to discontinue development of bexotegrast in IPF after reviewing safety and efficacy data. Additional communications have described scientific presentations at medical conferences, such as the American Thoracic Society International Conference, where the company has shared clinical and preclinical data related to fibrosis and biomarkers.
Corporate updates, including workforce and operational realignments, financial results and changes in executive roles, are also part of Pliant’s news record. Investors and followers of PLRX can use this page to review these categories of news—clinical trial updates, scientific presentations, program decisions and corporate announcements—in one place and revisit past disclosures as needed.
Pliant Therapeutics (Nasdaq: PLRX) reported significant advancements in its pipeline in 2021, highlighted by promising Phase 1b trial results for PLN-74809, which demonstrated up to 92% inhibition of TGF-β activation in healthy subjects. The company is actively progressing into 2022 with a focus on idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), including upcoming pivotal trials and regulatory developments. Financially, the company reported a net loss of $24.5 million in Q4 2021, an increase from the previous year, but maintains a robust cash position of $200.6 million to fund operations into mid-2023.
Pliant Therapeutics announced positive results from the expanded PLN-74809 Phase 1b trial, demonstrating significant TGF-β suppression in healthy participants, with reductions of up to 92% and 76% at 6 and 24 hours, respectively. The treatment was well tolerated, with no serious adverse events reported. This trial supports PLN-74809's potential as an antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and provides a favorable safety profile, contributing to de-risking ongoing Phase 2a trials.
Pliant Therapeutics (PLRX) announced the continuation of the INTEGRIS-IPF Phase 2a trial for PLN-74809, an oral treatment for idiopathic pulmonary fibrosis (IPF), without modifications following a positive recommendation from the Data Safety Monitoring Board (DSMB). The trial now progresses to evaluate a dosing increase to 320 mg daily over at least six months. PLN-74809 has demonstrated a favorable safety profile with over 450 participants showing no serious drug-related adverse events. Topline data is expected mid-2022.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology firm focused on fibrosis treatments, announced that Dr. Bernard Coulie will attend two upcoming conferences in March 2022. The first is the Cowen 42nd Annual Health Care Conference on March 8 at 2:10 p.m. ET, where he will join a respiratory/infections panel. The second is the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET, where he will present a company update. Presentations can be accessed via the investor relations page of Pliant’s website.
Pliant Therapeutics (PLRX) announced the completion of enrollment in its INTEGRIS-IPF Phase 2a clinical trial, evaluating PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The FDA has authorized long-term treatment evaluation of PLN-74809 at doses up to 320 mg. Topline data from the trial is expected mid-2022. The company plans to provide updates at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. The trial involves 84 patients over a 12-week period, assessing safety and efficacy metrics.
Pliant Therapeutics, a clinical stage biotechnology firm focused on fibrosis treatments, announced that its CEO, Bernard Coulie, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference.
The virtual presentation is scheduled for January 12, 2022, at 9:45 a.m. ET. Access is available via the Investor Relations' Events page on Pliant's website, with a replay option for 30 days post-event.
Pliant's lead candidate, PLN-74809, is in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company, announced participation in virtual fireside chats at upcoming investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will feature a pre-recorded chat on November 22, 2021, at 10:00am ET. The Evercore ISI 4th Annual HealthconX Conference will occur on November 30, 2021, at 3:30pm ET. Presentations can be accessed on Pliant's website, with audio available for 90 days post-event. Pliant is focused on developing therapies for fibrosis, including their lead candidate, PLN-74809.
Pliant Therapeutics (PLRX) released its third quarter 2021 financial results, showcasing productive progress in clinical trials. Positive interim data from the Phase 2a PET trial showed up to 98% αvβ6 target engagement in patients with idiopathic pulmonary fibrosis (IPF). Enrollment for ongoing trials INTEGRIS-IPF and INTEGRIS-PSC is on track, with topline data expected mid-2022. Research and development expenses rose to $21.1 million, contributing to a net loss of $27.0 million. The company maintains a robust cash position of $221.0 million, projected to sustain operations into 2023.
Pliant Therapeutics (Nasdaq: PLRX) announced that CEO Bernard Coulie will participate in a virtual fireside chat during Piper Sandler Lung Day on October 15, 2021, at 11:00 a.m. ET. This event will focus on the company's efforts in developing novel therapeutics for fibrosis, particularly its lead candidate, PLN-74809, which targets idiopathic pulmonary fibrosis and primary sclerosing cholangitis. A replay of the chat will be available on Pliant's website for 90 days post-event.
Pliant Therapeutics announced positive interim results from its Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The single-dose administration achieved up to 98% target engagement in the lungs, exceeding the predicted threshold for anti-fibrotic activity across all doses. The trial demonstrated a dose-dependent response and indicated that PLN-74809 targets fibrotic regions effectively. The ongoing trial aims to assess safety and pharmacokinetics, while the company anticipates future clinical outcomes based on these findings.